Impact of Point-of-care Xpert MTB/RIF on Tuberculosis Treatment Initiation: A Cluster Randomised Trial. by Lessells, RJ et al.
Lessells, RJ; Cooke, GS; McGrath, N; Nicol, MP; Newell, ML; Godfrey-
Faussett, P (2017) Impact of Point-of-care Xpert MTB/RIF on Tu-
berculosis Treatment Initiation: A Cluster Randomised Trial. Ameri-
can journal of respiratory and critical care medicine. ISSN 1073-449X
DOI: 10.1164/rccm.201702-0278OC
Downloaded from: http://researchonline.lshtm.ac.uk/4121148/
DOI: 10.1164/rccm.201702-0278OC
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
 
 
Impact of point-of-care Xpert MTB/RIF on tuberculosis treatment initiation: a cluster 
randomised trial 
 
Richard J Lessells 1,2, Graham S Cooke  3, Nuala McGrath 2,4, Mark P Nicol 5,6, Marie-Louise 
Newell 7, Peter Godfrey-Faussett 1    
 
1 Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, 
UK 
2 Africa Health Research Institute, Somkhele, South Africa 
3 Division of Infectious Diseases, Imperial College London, London, UK 
4 Academic Unit of Primary Care and Population Sciences and Department of Social Statistics 
and Demography, University of Southampton, Southampton, UK 
5 Division of Medical Microbiology and Institute for Infectious Diseases and Molecular 
Medicine, University of Cape Town, Cape Town, South Africa 
6 National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa 
7 Human Health and Development & Global Health Research Institute, Faculty of Medicine, 
University of Southampton, Southampton, UK 
 
Correspondence to: 
Dr Richard J Lessells 
Department of Clinical Research 
London School of Hygiene and Tropical Medicine 
Keppel Street 
 
 
London 
WC1E 7HT 
UK 
+44 (0)20 7636 8636 
richard.lessells@lshtm.ac.uk 
 
Author contributions: Conception and design: RJL, GSC, NM, MPN, MLN, PGF; 
Randomisation and cluster allocation: NM; Acquisition of data: RJL; Preparation of statistical 
analysis plan and data analysis: RJL, NM; Interpretation of data: RJL, GSC, NM, MPN, MLN, 
PGF; Drafting the manuscript: RJL; Revising the manuscript for important intellectual input: 
GSC, NM, MPN, MLN, PGF; Approval of final version of the manuscript: RJL, GSC, NM, 
MPN, MLN, PGF.  
 
Funding: This work was supported by the Wellcome Trust (grant number 090999/Z/09/Z, 
www.wellcome.ac.uk). GSC was supported by the BRC of Imperial College NHS Trust and the 
NIHR POC diagnostics DEC. NM was supported by the Wellcome Trust (grant number 
WT083495MA). The funders had no role in study design, data collection and analysis, decision 
to publish, or preparation of the manuscript. 
 
Running head: Point-of-care Xpert for TB diagnosis 
Descriptor: 11.1 Diagnosis of Tuberculosis or Latent Infection 
Word count: 3988 words 
 
 
 
At a Glance Commentary 
Scientific Knowledge on the Subject 
Centralised laboratory-based diagnostic systems for tuberculosis are associated with substantial 
loss to follow-up and delays prior to treatment. Whether decentralised, point-of-care diagnostic 
systems can reduce loss to follow-up and treatment delay has not been adequately investigated.  
What This Study Adds to the Field 
This is the first randomised trial to make a direct comparison between point-of-care and laboratory 
use of a molecular TB diagnostic. The point-of-care strategy shortened the time to appropriate 
treatment for people with rifampicin-susceptible TB; three-quarters of Xpert-positive/rifampicin-
susceptible cases received same-day diagnosis and treatment. Under both strategies, there were 
delays for people with drug-resistant TB and people with Xpert-negative/culture-positive TB, 
highlighting the need for more sensitive rapid diagnostics and further strengthening of health and 
laboratory systems. 
 
This article has an online data supplement, which is accessible from this issue's table of content 
online at www.atsjournals.org 
 
 
1 
 
Abstract 
 
Rationale: Point-of-care (POC) diagnostics have potential to reduce pre-treatment loss to 
follow-up and delays to initiation of appropriate TB treatment.  
 
Objective: To evaluate the effect of a POC diagnostic strategy on initiation of appropriate 
TB treatment. 
 
Methods: A cluster randomised trial of adults with cough who were HIV positive and/or at 
high risk of drug-resistant TB. Two-week time blocks were randomised to two strategies (i) 
Xpert performed at district hospital laboratory (ii) POC Xpert performed at primary health 
care clinic. All participants provided two sputum specimens: one for Xpert and the other for 
culture as reference standard. The primary outcome was the proportion of culture-positive 
pulmonary TB (PTB) cases initiated on appropriate TB treatment within 30 days.  
 
Measurements and Main Results: Between August 22, 2011 and March 1, 2013, 36 two-
week blocks were randomised and 1297 individuals were enrolled (646 in the laboratory arm, 
651 in the POC arm); 159 (12.4%) had culture-positive PTB. The proportion of culture-
positive PTB cases initiated on appropriate TB treatment within 30 days was 76.5% in the 
laboratory arm and 79·5% in the POC arm (odds ratio 1·13, 95% confidence interval [CI] 
0·51-2.53, p = 0·76; risk difference 3.1%, 95% CI -16.2, 10.1). The median time to initiation 
of appropriate treatment was 7 days (laboratory) vs. 1 day (POC). 
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Conclusions: POC positioning of Xpert led to more rapid initiation of appropriate TB 
treatment. Achieving one-stop diagnosis and treatment for all people with TB will require 
simpler, more sensitive diagnostics and broader strengthening of health systems.  
 
250 words 
 
Keywords: Tuberculosis, drug-resistant tuberculosis, molecular diagnostics, point-of-care 
systems, clinical trial  
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Introduction 
Tuberculosis (TB) remains one of the most important causes of global mortality, causing 
around 5000 deaths every day (1). In sub-Saharan Africa, the human immunodeficiency virus 
(HIV) epidemic and the spread of drug-resistant TB (DR-TB) contributed to a failure to 
achieve targets for reduction in TB prevalence and mortality in the United Nations 
Millennium Development Goals (MDG) (2). Timely detection and treatment of adult 
pulmonary TB cases is important, not only to limit individual morbidity and mortality but 
also to interrupt transmission. Centralised laboratory-based TB diagnostic systems are 
associated with substantial loss to follow-up and delays prior to treatment (3, 4). While 
diagnostics with improved sensitivity for detecting TB disease could have substantial clinical 
and public health impact, additional benefit might be achieved by positioning diagnostics at 
more peripheral levels of the health system (5, 6), however, there is little high quality 
evidence as to whether implementation of diagnostics at the point of care (POC) improves 
patient-relevant outcomes. 
 
This evidence is important to inform the scale-up of existing technologies and to guide the 
development of new diagnostics (7, 8). The aim of this trial was to determine whether a 
diagnostic strategy involving a rapid molecular test positioned at a rural primary health care 
(PHC) clinic would reduce delays and loss to follow-up prior to TB treatment, compared to a 
strategy with centralised laboratory testing.  
 
Methods 
Trial design 
The study was a cluster randomised trial of adults with possible pulmonary TB and DR-TB, 
evaluating the impact of Xpert MTB/RIF positioning on the initiation of appropriate TB 
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treatment (9). The unit of randomisation was a time period (two-week block), with each time 
period randomised either to a strategy with the Xpert MTB/RIF system placed in a centralised 
sub-district level laboratory (laboratory strategy) or at the clinic (POC strategy). A cluster 
represented the group of participants enrolled during the two-week block. The unit of 
observation was the individual participant. 
 
The trial was conducted in Hlabisa health sub-district, uMkhanyakude district, northern 
KwaZulu-Natal, South Africa; a predominantly rural area with a high burden of TB, DR-TB 
and HIV. In 2011 the TB notification rate for the sub-district was 1050 per 100 000 and HIV 
seroprevalence was 29% in the adult population aged 15-49 years (10). HIV and TB services 
are provided at 17 PHC clinics and one district hospital through decentralised collaborative 
programmes. Participants were recruited from the largest PHC clinic, situated approximately 
55km by road from the district hospital.  
 
The trial was approved by the Biomedical Research Ethics Committee of the University of 
KwaZulu-Natal (ref. BF033/11), the Ethics Committee of the London School of Hygiene and 
Tropical Medicine (ref. 5926), and the Health Research Committee of the KwaZulu-Natal 
Department of Health (ref. 084/11). The trial was registered with Current Controlled Trials 
on 17 June 2011 (ISRCTN 18642314) and with the South African National Clinical Trials 
Register on 10 July 2011 (DOH-27-0711-3568).   
 
Participants 
Adults (≥18 years) with possible pulmonary TB (defined as cough of any duration) were 
recruited at the clinic if they were HIV positive and/or had a high risk of DR-TB. These two 
groups were specified based on their high risk for mortality and prioritisation for Xpert 
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MTB/RIF testing at the time of the study (11). High risk of DR-TB was defined as per World 
Health Organization (WHO) case finding recommendations and South African national TB 
guidelines: failure of standard treatment regimen or retreatment regimen, smear non-
conversion at month 2 or 3 of standard treatment regimen or retreatment regimen, relapse or 
return after loss to follow-up, any other previous TB treatment, household exposure to known 
multidrug-resistant (MDR) or extensively drug-resistant (XDR)-TB case, health care worker, 
or prison inmate in previous 12 months (12, 13). Individuals were excluded if they had a 
previous diagnosis of MDR- or XDR-TB, were severely unwell requiring immediate 
admission to hospital, or were unable to give informed consent. In the event of enrolment of a 
participant on more than one occasion, only the data from the first enrolment was included in 
analysis. 
 
Procedures 
Potential participants were identified by clinic staff and referred to a research nurse for 
assessment. Individuals who were eligible for the study were given information about the 
study in the local language (isiZulu) and consent was indicated by signature or thumbprint. 
Clinical and demographic information was collected at enrolment by the research nurse. Two 
spontaneously expectorated sputum specimens were collected at the study site by the research 
nurse (the first for Xpert MTB/RIF and the second for culture). In both strategies, the nurse 
instructed participants to wait one hour between producing the first and the second specimen. 
Under the POC strategy, participants were advised to wait for their result or, if not possible, 
to return the next day. Under the laboratory strategy, participants were requested to return to 
the clinic for results after three working days, based on the typical turnaround time for receipt 
of sputum results at the time of the study.  
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A four-module GeneXpert system (Cepheid, Sunnyvale, CA) was installed for each two-
week time period at either the district hospital laboratory or the clinic according to the 
randomisation schedule. In the laboratory strategy, both sputum specimens were transported 
daily to the National Health Laboratory Service (NHLS) laboratory at the district hospital 
using the routine specimen transport system. Xpert MTB/RIF testing was performed by a 
laboratory technician and results were returned to the clinic using the routine transport 
system. For POC blocks, Xpert MTB/RIF was performed on site by the research nurse in a 
dedicated room (N95 respirator masks were used but no biosafety cabinet). If no valid result 
was obtained from the first test and there was sufficient sputum-buffer mix remaining, the 
test was repeated. If there was insufficient sputum-buffer mix or still no valid result, an 
additional sputum specimen was obtained from the participant at the earliest opportunity.  
 
Sputum specimens for culture were forwarded from the clinic via the routine specimen 
transport system to the district hospital laboratory and onwards the following day to the 
provincial reference laboratory in Durban. Mycobacterial growth indicator tubes (MGIT) 
were inoculated and incubated at 37°C for up to six weeks. Positive cultures were identified 
as M. tuberculosis complex using routine tests. The Genotype MTBDRplus assay was 
performed indirectly on culture isolates to identify mutations associated with rifampicin and 
isoniazid resistance. For isolates demonstrating rifampicin and/or isoniazid resistance, 
phenotypic drug susceptibility testing (DST) for rifampicin, isoniazid, ofloxacin, and 
kanamycin was performed. 
 
Clinical management followed standardised diagnostic and treatment algorithms (see Figures 
E1-E2 in the online data supplement). The research nurse worked in parallel with the TB 
nurses at the clinic but in a separate room; the research nurse coordinated further 
7 
 
management for trial participants following routine clinic practice (see further details in 
online data supplement). X-ray facilities were not available at the clinic, only at the district 
hospital. A medical officer was present at the clinic one day per week but any adults that 
required further evaluation for TB were referred to the district hospital. Throughout the study 
period, all participants with rifampicin-resistant TB were admitted to the district hospital and 
referred to the provincial DR-TB unit in Durban for initiation of DR-TB treatment (further 
details are provided in the online data supplement) (14). 
 
Clinic review for outcome evaluation was scheduled two months after the enrolment visit. 
The research nurse collected information regarding initiation of TB treatment, antiretroviral 
therapy (ART) and hospitalisation. Outcome evaluation was not blinded to randomisation 
group. If the participant did not attend clinic for follow-up evaluation, information was 
obtained by telephone or from clinic registers.  
 
Outcomes 
The primary outcome was the proportion of culture-positive PTB cases initiated on 
appropriate TB treatment within 30 days of enrolment. Appropriate treatment was defined 
according to the results of genotypic and phenotypic tests on the culture isolate (see Table 1 
in the online data supplement). Secondary outcomes were: time to initiation of appropriate 
TB treatment for culture-positive pulmonary TB cases; time to initiation of appropriate DR-
TB treatment (for rifampicin-resistant TB cases); all-cause mortality at 60 days; proportion of 
participants with at least one hospital admission within 60 days; and time to initiation of ART 
for HIV-positive participants. 
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Sample size 
The study was designed to detect a 10 percentage point increase in the proportion of culture-
positive PTB cases initiated on appropriate treatment within 30 days (from 85% in the 
laboratory arm). Sample size was calculated with the equation of Hayes and Bennett, using 
the coefficient of variation (κ) (15). With κ=0·05 and a cluster size of 12 culture-positive 
cases we needed 16 clusters and 188 culture-positive TB cases in each arm to detect this 
difference with 95% confidence and 80% power. We assumed 10% of individual participants 
would be lost to follow-up, so we needed 208 culture-positive TB cases in each arm. Based 
on the assumption that 25% of adults with possible pulmonary TB would have a positive 
culture, the study was initially planned to enrol 1664 participants. 
 
Randomisation 
The allocation schedule for random assignment of two-week blocks was computer generated, 
using random permuted blocks of eight. Due to extension of the trial, an extra four blocks 
were randomised. Allocation for each clinic block was placed into sequentially numbered, 
opaque, sealed envelopes; the envelope was opened on the Friday before the start of a new 
two-week block and the allocated strategy for the next time block was communicated to study 
staff.  
 
Statistical methods 
Analysis of baseline characteristics was performed to characterise the trial population and to 
identify any baseline imbalances between the study arms. All analyses were individual-level 
intention-to-treat analyses which took account of within-cluster correlation. The primary 
analysis excluded TB cases on treatment at the time of enrolment with a M. tuberculosis 
culture isolate susceptible to rifampicin and isoniazid, as appropriate treatment for these cases 
would involve continuation of the same drug regimen. Regression modelling using 
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generalized estimating equations (GEE) with a binomial distribution function and a logit link 
was applied, specifying an exchangeable working correlation matrix. Any important 
individual-level characteristics that were unbalanced between arms were considered in the 
model as covariates. For the secondary outcomes with binary variables, GEE models were 
also fitted with a binomial distribution function and a logit link. For the secondary outcomes 
with time-to-event measures, Cox proportional hazard models were used with the shared 
frailty option to account for clustering by time block. All times were measured from the 
enrolment date. The proportional hazards assumption was examined graphically using the 
log-log plot and using the score test based on scaled Schoenfeld residuals (16). Time-to-event 
data were also plotted as Kaplan-Meier survival curves and the two groups were compared 
using the log rank test. For the Kaplan-Meier analysis, deaths were censored at 60 days (17). 
All analyses were performed using Stata version 13.1 (Stata Corporation, College Station, 
TX). 
 
Results 
Between 22 August 2011 and 1 March 2013, 36 two-week blocks were randomised to one of 
the two diagnostic strategies (Figure 1). In July 2012, following the identification of a 
shortfall in the enrolment of culture-positive cases, the Trial Steering Committee 
recommended measures to optimise recruitment and to maximise the yield from sputum 
cultures. Despite implementation of these measures, enrolment remained below target but due 
to time and logistical constraints the enrolment phase could not be extended beyond March 
2013. With the numbers recruited, the power of the study to detect a 10% difference in the 
primary endpoint was 55%.  
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A total of 1526 individuals were screened and 1297 enrolled in the trial (Figure 1). Data from 
sixteen participants were excluded from all analyses due to duplicate enrolment (n = 14) or 
incorrect criteria for TB drug resistance risk (n = 2), giving 1281 individuals for analysis 
(mean 36 per cluster, range 19-56). Altogether, 1185 (92·5%) were HIV positive and 577 
(45·0%) had documented risk of DR-TB. The baseline characteristics of the individual 
participants were well balanced (Table 1).  
 
Overall, 1235 participants (96·4%) submitted two sputum specimens. The proportion of 
initial specimens from which no Xpert MTB/RIF result was obtained was higher with the 
laboratory strategy than the POC strategy (7·8% vs. 1·1%, p < 0.001), mostly due to 
specimen leakage in transit (Table 2). The overall proportion of participants with a culture 
positive for M. tuberculosis was 12·9% (159/1235); this was higher in the POC arm than the 
laboratory arm (14·8% vs. 11·0%, p = 0·06) (see Table 2 in the online data supplement). 
Thirty-two (20·1%) M. tuberculosis isolates were rifampicin resistant (see Tables E3-E4 in 
the online data supplement). Almost one in four specimens (281/1235, 22·8%) did not yield a 
valid culture result: 133 (10·8%) specimens leaked in transit, 103 (8·3%) cultures were 
contaminated, and 46 (3·7%) had no documented result. Participants with and without a valid 
culture result had similar baseline characteristics (see Table E5 in the online data 
supplement). 
 
Outcomes were evaluated for all 159 culture-positive cases a median of 90 days (IQR 72-
153) post-enrolment. Three culture-positive cases were excluded from the primary analysis as 
they were on TB treatment at enrolment and the M. tuberculosis culture isolate was 
susceptible to rifampicin and isoniazid. The population for analysis therefore included 156 
culture-positive PTB cases (68 in laboratory arm; 88 in POC arm). The baseline 
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characteristics of the culture-positive cases were well balanced (Table 3). The proportion of 
culture-positive PTB cases initiated on appropriate TB treatment within 30 days of enrolment 
was 76·5% (52/68) with the laboratory strategy and 79·5% (70/88) with the POC strategy 
(odds ratio (OR) 1·13, 95% confidence interval (CI) 0·51-2·53, p = 0·76; risk difference 
3.1%, 95% CI -16.2, 10.1). The estimated value of the coefficient of variation (κ) was 0·11.  
 
For Xpert-positive/culture-positive cases, 51/57 (89·5%, 95% CI 78·9-95·1) in the laboratory 
arm and 65/68 (95·6%, 95% CI 87·8-98·5) in the POC arm started appropriate TB treatment 
within 30 days (Table 4). The majority of Xpert-negative/culture-positive cases did not start 
appropriate treatment within 30 days (see further details in the online data supplement). 
Overall, 215 participants started TB treatment within 60 days, 154 (71·6%) on the basis of a 
positive Xpert result, 14 (6·5%) on the basis of a positive culture, and 45 on clinical or 
radiological grounds (3.5% of all enrolled or 20.9% of those who started treatment). For two 
participants the basis for starting treatment was not known. Seven (15·6%) of those cases 
treated empirically had a subsequent positive culture. 
 
For the analysis of time to appropriate treatment, 156 culture-positive TB cases contributed 
2413 days follow-up (median 5·5 days, IQR 1·0-22·5). In the Cox regression model for time 
to appropriate TB treatment, the proportional hazards assumption was not met. Time to 
appropriate TB treatment was plotted as Kaplan-Meier survival curves (Figure 2). Six 
participants (all in the POC arm) died prior to initiation of appropriate TB treatment. The 
estimated median time to appropriate treatment was 7 days (95% CI 6-10) under the 
laboratory strategy and 1 day (95% CI 1-2) under the POC strategy. Under the POC strategy, 
34 cases commenced appropriate treatment on the day of enrolment (50·0% of Xpert-
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positive/culture-positive cases; 75.6% of rifampicin-susceptible Xpert-positive/culture-
positive cases).  
 
Thirty-two rifampicin-resistant cases contributed 976 days follow-up (median 23·5 days, IQR 
14·5-56·0). In the Cox regression model for time to appropriate TB treatment, the 
proportional hazards assumption was not met. Two cases died before the initiation of 
appropriate treatment. Kaplan-Meier curves for time to appropriate TB treatment by arm for 
the rifampicin-resistant cases are shown in Figure 3. The estimated median time to treatment 
was 27 days (95% CI 22-51) under the laboratory strategy and 17 days (95% CI 10-60) in the 
POC arm.  
 
For the analyses involving all participants with possible TB or DR-TB, 28·3% (362/1281) 
had no post-enrolment follow-up (28·0% for laboratory arm vs. 28·5% for POC arm). 
Participants with no post-enrolment follow-up were less likely to be on ART and had 
marginally higher CD4+ cell counts at enrolment, but were otherwise similar to those whose 
outcome was evaluated (see Table E6 in the online data supplement). Figure E3 in the online 
data supplement shows the outcomes at day 60 for all trial participants. Overall, 24 (2·6%) 
participants died within 60 days of enrolment, a greater proportion in the POC arm (3·5%, 
95% CI 2·2-5·6) compared to the laboratory arm (1·7%, 95% CI 0·9-3·4): OR 2·33, 95% CI 
1·13-4·80 (p = 0·022); risk difference -1.8%, 95% CI -3.8, 0.3. After adjustment for baseline 
CD4+ T-cell count and culture result, this difference did not reach statistical significance 
(aOR 1·92, 95% CI 0·89-4·16 (p = 0·096). A similar proportion of participants in the two 
arms were admitted to hospital within 60 days of enrolment (2.0% in laboratory arm vs. 3.1% 
in POC arm): OR 1·60, 95% CI 0·68-3·77 (p = 0·286); risk difference -1.1%, 95% CI -3.1, 
0.9. The estimated median time to ART initiation for HIV-positive participants eligible for 
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but not yet receiving ART was 24·1 days (95% CI 22·1-32·1) in the laboratory arm and 20·1 
days (95% CI 17·1-22·1) in the POC arm. There was no evidence that time to ART initiation 
was different according to Xpert placement (HR 1·22, 95% CI 0·91-1·64, p = 0·184).  
 
An exploratory post hoc analysis was performed to explore the effect of POC positioning on 
treatment initiation at different time thresholds (2 days, 5 days, and 14 days from enrolment). 
The proportion of culture-positive cases that had initiated appropriate treatment was 
significantly greater in the POC arm at all three time points (Table 5).  
 
 
Discussion 
This is the first randomised trial to evaluate the effect of providing point-of-care molecular 
diagnostics for adults with possible pulmonary TB and DR-TB in a rural primary health care 
setting. Our data complement those from randomised trials that have compared Xpert to 
smear microscopy in similar southern African settings (18-20); and other non-randomised 
studies that have explored the impact of decentralised Xpert testing (21-23). 
 
Point-of-care placement shortened the time to initiation of appropriate TB treatment and 
enabled same-day diagnosis and treatment for half of the Xpert-positive/culture-positive 
cases. With POC placement, almost all Xpert-positive, rifampicin-susceptible cases started 
treatment within the national target of two days (24). The failure to achieve same-day 
treatment for all people with a positive Xpert was partly explained by people choosing not to 
wait for same-day results and restricted Xpert operating hours. Other studies have also shown 
that POC implementation does not automatically translate to same-day treatment and 
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collectively this evidence highlights the need for innovation in both technology and health 
systems to enable same-day treatment for all TB cases (21-23, 25). 
 
Although the proportion of individuals initiating appropriate treatment within 30 days was 
higher in the POC arm, this did not reach statistical significance. Our ability to detect a 
difference between the two strategies at 30 days was limited by low statistical power. The 
power of the study was reduced primarily by the lower than expected proportion of 
participants with culture positive tuberculosis, as well as slightly higher than expected 
between-cluster variability. Our post hoc analysis showed a significant difference in 
proportions of individuals starting treatment (at days two, five, and 14), suggesting that the 
POC strategy did have the intended effect in facilitating earlier treatment. We selected the 
threshold of 30 days on the basis of our considered opinion of what would be seen to be of 
clinical and public health relevance, but with the benefit of hindsight this was probably not 
the ideal endpoint. Many different study designs and outcomes have been used in TB 
diagnostic research and this is an area that would certainly benefit from more consensus (26).  
 
Pre-treatment loss to follow-up was lower than expected under the laboratory strategy. Of the 
Xpert-positive rifampicin-susceptible cases in the laboratory arm, only two (4%) did not start 
any treatment within 30 days. This suggests that the routine measures to recall those who 
tested positive and who did not initially return functioned well during the trial. It is possible 
that this was partly due to the Hawthorne effect (27), or that the study personnel helped to 
improve the routine systems. However, analysis of routine laboratory and programme data 
has shown that pre-treatment loss to follow-up has reduced in this area in the last few years, 
and is lower than other published data from South Africa (19): in 2014 in seven clinics in the 
same area (including the study clinic), pre-treatment loss to follow-up for people with 
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positive Xpert (rifampicin susceptible) was 5% (unpublished data). Under the standard-of-
care strategy, the laboratory and specimen transport systems worked better than we had 
expected. This suggests that while the results may be generalizable within South Africa, POC 
systems may have greater impact in settings where logistics and laboratory systems preclude 
the prompt return of results.       
 
 
Whether the shorter time to treatment initiation and fewer pre-treatment clinic visits observed 
in this study could result in public health benefit, in terms of reducing transmission, is a 
question that remains to be tested. Given that the median reported duration of cough was two 
weeks, shortening the time to appropriate TB treatment by six days could have an important 
effect on the overall infectious time. A reduction in time to appropriate treatment is of 
particular importance for drug-resistant TB, yet rifampicin resistance was the main reason for 
treatment delay in both arms. During preparation for the trial, it was anticipated that the 
district hospital would become a fully decentralised DR-TB treatment site (28). However, this 
did not happen according to anticipated timelines and throughout the study period people 
with DR-TB had to be referred to the provincial DR-TB unit in Durban (~250km) for 
treatment initiation. The delay between referral and the initial visit at the provincial DR-TB 
unit was the main component of the overall delay to DR-TB treatment initiation. 
Nevertheless, the time to initiation of DR-TB treatment for both strategies was comparable to 
other programmes in South Africa (29, 30); but longer than the median time of seven days 
achieved by one decentralised DR-TB programme in Cape Town (31). These data emphasise 
how novel molecular diagnostics may have greatest impact when access to treatment is not 
limited. 
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Cost-effectiveness analyses have suggested that POC placement of Xpert MTB/RIF at current 
prices would need to produce substantial clinical benefits to offset the increased costs 
associated with primary health care clinic deployment in South Africa, although these 
analysed only health system costs without consideration of patient costs (32). In that analysis, 
the increased costs were related to the need for more instruments and staff, and to the 
decreased operational efficiency at clinic level. Although economic analysis is beyond the 
scope of this paper, our findings to some extent support this notion as even in this busy 
primary health care clinic, the system was never operating at full capacity. However, the 
nurse was easily trained to use the system and was able to do this amongst other duties. The 
big difference for POC deployment would therefore be the capital expenditure costs for 
instruments, which would be depreciated over the next few years. Given that the benefits 
could be greater with further decentralisation of DR-TB care or in settings with weaker 
laboratory systems, we still need better understanding of the cost drivers to inform diagnostic 
systems in different settings. With respect to patient costs, the shorter time to treatment and 
fewer clinic visits, particularly same-day treatment, could have particular benefit in rural 
communities such as this, where one in two people with TB incur catastrophic costs (33, 34).  
 
With new technologies being developed that may be more convenient for decentralised use 
(35), this study provides rare real-world evidence of the benefits and limitations of point-of-
care diagnostics. The findings from this cluster randomised trial suggest that strengthening of 
the diagnostic cascade to get all TB cases on treatment in a timely fashion will require a 
combination of technological advances (simpler, more sensitive diagnostics better suited for 
point-of-care use (35, 36)) allied with broader strengthening of health systems to limit 
treatment delays, especially for drug-resistant TB (37). There remains a need to push for the 
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development of simple diagnostic technologies suitable for true POC use and affordable for 
widespread use (7, 8, 38). 
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Figure legends  
 
Figure 1 Study flow diagram for clusters and individual participants 
Figure 2 Kaplan-Meier curves for time to initiation of appropriate TB treatment before death 
for culture-positive cases 
Figure 3 Kaplan-Meier curves for time to initiation of appropriate TB treatment before death 
for culture-positive rifampicin-resistant cases 
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Table 1 Baseline demographic and clinical characteristics for participants with possible TB or drug-resistant TB 
Variable  Laboratory 
(n = 640) 
Point-of-care 
(n = 641) 
Sex Female (n, %) 393 (61·4) 422 (65·8) 
Age (years) Median (IQR) 36 (30-43) 36 (28-45) 
Body mass index (kg/m2) Median (IQR) 22·6 (20·2-26·5) 22·9 (20·1-27·0) 
Current symptoms Cough only (n, %) 157 (24·5) 147 (22·9) 
 Weight loss (n, %) 332 (51·9) 335 (52·3) 
 Fever (n, %) 269 (42·0) 256 (40·0) 
 Night sweats (n, %) 295 (46·2) 298 (46·7) 
Duration of cough (weeks)* Median (IQR) 2 (1-4) 3 (1-4) 
Current IPT use Yes (n, %) 8 (1·3) 11 (1·7) 
Risk of drug resistance None (n, %) 351 (54·8) 353 (55·1) 
 Treatment failure (n, %) 4 (0·6) 7 (1·1) 
 Smear non-conversion (n, %) 18 (2·8) 21 (3·3) 
 Previous TB treatment (n, %) 253 (39·5) 247 (38·5) 
 Household contact (n, %) 22 (3·4) 15 (2·3) 
 Health care worker (n, %) 12 (1·9) 9 (1·4) 
 Prison last 12 months (n, %) 7 (1·1) 10 (1·6) 
HIV status  Positive (n, %) 589 (92·0) 596 (93·0) 
 Negative (n, %) 39 (6·1) 39 (6·1) 
 Never tested (n, %) 6 (0·9) 3 (0·5) 
 Not disclosed (n, %) 5 (0·8) 3 (0·5) 
 Missing (n, %) 1 (0·2) 0 
Antiretroviral therapy† Current (n, %) 238 (40·4) 222 (37·3) 
CD4+ cell count (cells/µL)†‡ Median (IQR) 280 (147-455) 247 (119-415) 
 ≤50 (n, %) 41 (6·4) 66 (10·3) 
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 51-200 (n, %) 152 (23·8) 150 (23·4) 
 201-350 (n, %) 149 (23·3) 158 (24·6) 
 351-500 (n, %) 85 (13·3) 81 (12·6) 
 >500 (n, %) 108 (16·9) 92 (14·4) 
 Missing (n, %) 54 (8·4) 49 (7·6) 
* Cough duration missing for 11 participants (laboratory, n = 3; point-of-care, n = 8)  
† Proportions are of HIV-positive participants 
‡ CD4+ cell count up to 18 months prior to or 30 days after enrolment 
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Table 2 Results from Xpert MTB/RIF tests 
Xpert MTB/RIF result Laboratory 
(n = 619) 
Point-of-care 
(n = 616) 
First sputum specimen   
MTB DETECTED 98 (15·8) 108 (17·5) 
Rif Resistance NOT DETECTED 82 (13·2) 91 (14·8) 
Rif Resistance DETECTED 16 (2·6) 17 (2·8) 
MTB NOT DETECTED 473 (76·4) 501 (81·3) 
INVALID 6 (1·0) 4 (0·6) 
ERROR 5 (0·8) 2 (0·3) 
Not processed (specimen leaked) 37 (6·0) 1 (0·2) 
All sputum specimens   
MTB DETECTED 105 (17·0) 108 (17·5) 
Rif Resistance NOT DETECTED 87 (14·1) 91 (14·8) 
Rif Resistance DETECTED 18 (2·9) 17 (2·8) 
MTB NOT DETECTED 505 (81·6) 502 (81·5) 
INVALID 1 (0·2) 3 (0·5) 
ERROR 1 (0·2) 2 (0·3) 
Not processed (specimen leaked) 7 (1·1) 1 (0·2) 
40/48 participants in laboratory arm with no valid result from the first sputum specimen submitted a second 
specimen after a median of 5 days (IQR 4-8); all but one of the repeat specimens yielded a valid result. One 
participant in point-of-care arm with an invalid result on the first sputum specimen submitted a second specimen on 
the same day which yielded a valid result; six other participants in the point-of-care arm with no valid result from 
the first sputum specimen did not submit a second specimen. 
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Table 3 Baseline demographic and clinical characteristics for culture-positive TB cases included in primary analysis 
 Variable  Laboratory 
(n = 69) 
Point-of-care 
(n = 88) 
Sex Female (n, %) 32 (47·1) 53 (60·2) 
Age (years) Median (IQR) 34 (28-41) 33 (27-41) 
Body mass index (kg/m2) Median (IQR) 20·5 (18·2-22·0) 21·0 (18·6-25·0) 
Current symptoms Cough only (n, %) 9 (13·2) 10 (11·4) 
 Weight loss (n, %) 53 (77·9) 67 (76·1) 
 Fever (n, %) 28 (41·2) 34 (38·6) 
 Night sweats (n, %) 39 (57·4) 50 (56·8) 
Duration of cough (weeks) Median (IQR) 3 (1-6) 3 (2-4) 
Current IPT use Yes (n, %) 1 (1·5) 1 (1·1) 
Risk of drug resistance None (n, %) 33 (48·5) 52 (59·1) 
 Treatment failure (n, %) 1 (1·5) 2 (2·3) 
 Smear non-conversion (n, %) 3 (4·4) 3 (3·4) 
 Previous TB treatment (n, %) 30 (44·1) 31 (35·2) 
 Household contact (n, %) 6 (8·8) 4 (4·6) 
 Health care worker (n, %) - - 
 Prison last 12 months (n, %) 1 (1·5) 2 (2·3) 
HIV status  Positive (n, %) 64 (94·1) 87 (98·9) 
 Negative (n, %) 3 (4·4) 1 (1·1) 
 Never tested (n, %) 1 (1·5) - 
 Not disclosed (n, %) - - 
 Missing (n, %) - - 
Antiretroviral therapy* Current (n, %) 19 (29·7) 31 (35·6) 
CD4+ cell count (cells/µL)*† Median (IQR) 219 (98-371) 203 (99-328) 
 ≤50 (n, %) 6 (8·8) 10 (11·4) 
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 51-200 (n, %) 21 (30·9) 29 (33·0) 
 201-350 (n, %) 14 (20·6) 24 (27·3) 
 351-500 (n, %) 12 (17·6) 8 (9·1) 
 >500 (n, %) 7 (10·3) 9 (10·2) 
 Missing (n, %) 8 (11·8) 8 (9·1) 
* Proportions are of HIV-positive participants 
† CD4+ cell count up to 18 months prior to or 30 days after enrolment 
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Table 4 Proportion of culture-positive pulmonary TB cases who started appropriate TB treatment within 30 days, 
according to Xpert MTB/RIF result 
 Laboratory Point-of-care 
30 days   
Xpert positive 51/57 (89·5%) 65/68 (95·6%) 
Xpert positive – rifampicin susceptible 42/45* (93·3%) 55/56† (98·2%) 
Xpert positive – rifampicin resistant 9/12‡ (75·0%) 10/12 (83·3%) 
Xpert negative 0/10 5/20§ (25·0%) 
Xpert no result 1/1ǁ (100%) - 
Total 52/68 (76·5%) 70/88 (79·6%) 
60 days   
Xpert positive 53/57 (93.0%) 65/68 (95.6%) 
Xpert positive – rifampicin susceptible 42/45 (93.3%) 55/56 (98.2%) 
Xpert positive – rifampicin resistant 11/12 (91.7%) 10/12 (83.3%) 
Xpert negative 4/10 (40.0%) 11/20 (55.0%) 
Xpert no result 1/1 (100%) - 
Total 58/68 (85.3%) 76/88 (86.4%) 
 
* One participant with multidrug resistance on culture isolate but rifampicin susceptibility on Xpert initiated 
inappropriate TB treatment after 3 days (switched to appropriate treatment beyond 30 days) 
† One participant with multidrug resistance on culture isolate but rifampicin susceptibility on Xpert initiated 
inappropriate TB treatment on the day of enrolment (switched to appropriate treatment  beyond 30 days) 
‡ One participant with isoniazid monoresistance on culture isolate but rifampicin resistance on Xpert initiated 
inappropriate TB treatment after 15 days  
§ Four participants with negative Xpert started treatment on basis of chest X-ray (after 1, 8, 11, and 14 days 
respectively); one participant started treatment on basis of positive culture (after 30 days) 
ǁ One participant with no Xpert result (specimen leaked) started treatment on basis of clinical features (after 1 day) 
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Table 5 Exploratory analyses with different time thresholds for initiation of appropriate anti-TB treatment  
Time 
threshold 
Laboratory arm (n = 68)  Point-of-care arm (n = 88) Odds ratio (95% 
CI) 
p value 
 n % (95% CI)  n % (95% CI)   
2 days 5 7.4 (2.4-16.3)  53 60.2 (49.2-70.5) 17.1 (5.3-55.1) <0.001 
5 days 22 32.4 (21.5-44.8)  56 63.6 (52.7-73.6) 3.6 (1.8-7.3) <0.001 
14 days 42 61.8 (49.2-73.3)  66 75.0 (64.6-83.6) 1.9 (1.0-3.6) 0.057 
CI, confidence interval 
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Figure 1 Study flow diagram for clusters and individual participants 
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Figure 2 Kaplan-Meier curves for time to initiation of appropriate TB treatment before death for culture-positive 
cases 
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Figure 3 Kaplan-Meier curves for time to initiation of appropriate TB treatment before death for culture-positive 
rifampicin-resistant cases 
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Methods 
Clinical management of participants 
The Xpert MTB/RIF assay was incorporated into diagnostic algorithms adapted from the WHO 
standardised diagnostic algorithms for HIV-infected individuals with possible TB and 
individuals at high risk of drug-resistant TB (Figures E1 & E2) (E1). 
 
The research nurse worked alongside the TB nurses at the primary health care clinic at all times. 
The research nurse was located in a separate room in a parkhome adjoining the TB department. 
The research nurse was responsible for sputum specimen collection and delivery of specimens to 
the courier. When participants did not return as scheduled to receive their Xpert results, the 
research nurse was responsible for contacting participants to encourage them to return. This 
procedure was aligned with the routine clinic systems at the time of the study. Results were not 
communicated to participants by short message service (SMS). Referrals for further diagnostic 
evaluation at the district hospital (e.g. chest X-ray or medical officer review) were organised by 
the research nurse in close collaboration with the TB nurses.       
 
Pathways for referral and treatment of drug-resistant TB cases 
All participants diagnosed with drug-resistant TB (DR-TB) were seen by a medical officer at the 
clinic or at the district hospital and then referred to the provincial DR-TB centre, King Dinuzulu 
Hospital (formerly King George V Hospital) in Durban for specialist assessment and treatment 
initiation. Appointments at King Dinuzulu Hospital were booked by the medical officer after 
reviewing the participant. Generally, people with DR-TB were admitted to the TB inpatient ward 
at Hlabisa Hospital two to three days before their scheduled appointment, travelled to Durban on 
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an outpatient basis, and then stayed at Hlabisa at least one month for supervision of treatment 
and monitoring for toxicity under the satellite model (E2). Following the first month, if patients 
were clinically stable, treatment continued at home (injectable agents were given at the nearest 
PHC clinic or by a mobile injection team) and patients made monthly visits to King Dinuzulu 
Hospital for follow-up and pharmacy refill. Patients with XDR-TB or complicated MDR-TB 
(pregnant females, renal failure, or liver failure) were admitted to King Dinuzulu Hospital for 
specialist inpatient management. 
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Results 
Culture and drug susceptibility test (DST) results 
The results of the Mycobacterial Growth Indicator Tube (MGIT) culture are shown in Table E2. 
The overall yield from culture was lower than that from Xpert MTB/RIF with 12.9% (159/1235) 
of participants having a culture positive for M. tuberculosis, compared to 16.7% (206/1235) 
having a positive Xpert from the initial sputum specimen. Considering only results of specimens 
that were processed and where a result could be identified, 15.0% (159/1057) of cultures were 
positive for M. tuberculosis.  
 
Of the 159 culture isolates identified as M. tuberculosis, 32 (20.1%) were rifampicin resistant by 
line probe assay (LPA) and/or phenotypic drug susceptibility testing (DST) (Table E3). 
Phenotypic drug susceptibility testing was performed if the LPA detected isoniazid and/or 
rifampicin resistance or if LPA results were indeterminate. For the purposes of analysis, 
rifampicin resistance was defined as an isolate with rifampicin resistance on either or both tests 
(LPA and phenotypic DST). Twenty-eight isolates were resistant to rifampicin by LPA and thirty 
were resistant to rifampicin by phenotypic DST. Concordance between the two methods was 
good (Table E4).  
 
The characteristics of the participants with an evaluable culture result, defined as positive for M. 
tuberculosis, positive for NTM, positive with no definitive identification or negative, were 
compared with the characteristics of those without an evaluable result. The two groups were 
broadly comparable, except that those without an evaluable result were less likely to be HIV 
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positive, and those that were HIV positive had lower CD4+ T-cell counts and were somewhat 
less likely to be on ART (Table E5). 
 
Initiation of inappropriate treatment 
Three participants initiated anti-TB treatment within 30 days that was defined as inappropriate 
according to the drug susceptibility pattern (two in the laboratory arm and one in the point-of-
care arm). In all three cases, this was due to discordant rifampicin resistance results: in two cases 
defined as MDR-TB by LPA and phenotypic DST, Xpert was reported as rifampicin susceptible 
and standard first-line anti-TB treatment was started; in the third case defined as isoniazid mono-
resistant by LPA and phenotypic DST (rifampicin susceptible on both LPA and phenotypic 
DST), Xpert detected rifampicin resistance and MDR-TB treatment was initiated. 
 
Outcomes for Xpert negative/culture positive cases 
The majority (26/31, 83.9%) of Xpert negative/culture positive cases did not initiate appropriate 
TB treatment within 30 days. Approximately half (16/31, 51.6%) did not initiate appropriate 
treatment within 60 days.  
 
In the laboratory strategy, none of 11 Xpert negative/culture positive cases started appropriate 
TB treatment within 30 days. Of the eight cases with fully susceptible TB, five (62.5%) started 
appropriate TB treatment on the basis of the positive culture (after 37, 55, 58, 86 and 92 days) 
and three were not recorded as having started treatment. Of the three cases with rifampicin-
resistant TB (all with MDR-TB), all three started drug-resistant TB treatment (after 51, 92, and 
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125 days) respectively; one of those cases had initially commenced standard first-line TB 
treatment on the basis of the preliminary positive culture result before DST results. 
  
In the POC strategy, 5/20 (25.0%) of Xpert negative/culture positive cases commenced 
appropriate TB treatment within 30 days, four on the basis of chest X-ray and one on the basis of 
the positive culture (all five had fully susceptible TB). Of the remaining 12 cases with fully 
susceptible TB, two commenced treatment on the basis of chest X-ray (after 45 and 58 days), 
four commenced treatment on the basis of the positive culture (after 35, 40, 55, and 57 days), 
three participants died, and three were not recorded as having started TB treatment. Of the three 
cases with rifampicin-resistant TB (all with MDR-TB), one commenced drug-resistant TB 
treatment (after 125 days), one died after commencing standard first-line TB treatment (on the 
basis of the positive culture results before DST results), and one was not recorded as having 
started any TB treatment. 
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Table E1 Definitions of appropriate TB treatment for primary and secondary endpoints 
Case definition* Appropriate initial anti-TB drug regimen 
M. tuberculosis susceptible to rifampicin and isoniazid Isoniazid + rifampicin + pyrazinamide + ethambutol ± streptomycin 
M. tuberculosis with mono-resistance to isoniazid Isoniazid + rifampicin + pyrazinamide + ethambutol ± streptomycin 
M. tuberculosis with mono-resistance to rifampicin Standardised second-line regimen‡ (kanamycin/amikacin + fluoroquinolone + ethionamide + 
cycloserine/terizidone ± pyrazinamide ± ethambutol) ± isoniazid 
Multidrug-resistant M. tuberculosis  (MDR-TB): resistance to 
rifampicin and isoniazid  
Standardised second-line regimen‡ (kanamycin/amikacin + fluoroquinolone + ethionamide + 
cycloserine/terizidone ± pyrazinamide ± ethambutol) 
Extensively drug-resistant M. tuberculosis (XDR-TB): MDR plus 
resistance to ofloxacin and kanamycin 
Standardised XDR-TB regimen‡ (capreomycin + fluoroquinolone + ethionamide + 
cycloserine/terizidone + PAS + clofazimine)  
M. tuberculosis with unknown drug susceptibility† Isoniazid + rifampicin + pyrazinamide + ethambutol 
PAS, para-aminosalicylic acid 
* Case definition based on results of MGIT culture + line probe assay + phenotypic DST 
† Drug susceptibility test not performed or unsuccessful 
‡ According to national treatment guidelines (E3) 
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Table E2 Results of Mycobacterial Growth Indicator Tube (MGIT) culture 
Result Laboratory 
(n = 619) 
Point-of-care 
(n = 616) 
Positive (M. tuberculosis) 68 (11.0) 91 (14.8) 
Positive (non-tuberculous mycobacteria) 7 (1.1) 6 (1.0) 
Positive (no identification) 1 (0.2) - 
Negative 402 (64.9) 379 (61.5) 
Contaminated 56 (9.0) 47 (7.6) 
Not processed 71 (11.5) 71 (11.5) 
Specimen leaked in transit 63(10.2) 70 (11.4) 
Incorrect details* 2 (0.3) 0 
Processed for smear microscopy† 6 (1.0) 1 (0.2) 
No result 14 (2.3) 22 (3.6) 
* Participant details on laboratory form and specimen container did not match 
† Specimen processed for smear microscopy in error instead of culture 
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Table E3 Results of drug susceptibility testing (combined from line probe assay and phenotypic drug 
susceptibility testing) 
Result Laboratory 
(n = 68) 
Point-of-care 
(n = 91) 
Rifampicin and isoniazid susceptible 51 (75.0) 72 (79.1) 
Isoniazid susceptible, rifampicin indeterminate* - 1 (1.1) 
Rifampicin mono resistance 2 (2.9) 1 (1.1) 
Isoniazid mono resistance 1 (1.5) 2 (2.2) 
Rifampicin + isoniazid resistance  14 (20.6) 15 (16.5) 
* Line probe assay reported as isoniazid susceptible, rifampicin inconclusive; phenotypic DST unsuccessful 
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Table E4 Concordance between line probe assay and phenotypic DST for rifampicin & isoniazid 
Line probe assay result Phenotypic DST result 
Rifampicin  Isoniazid 
Susceptible Resistant Inconclusive  Susceptible Resistant Inconclusive 
Susceptible 3 1 0  3 2 0 
Resistant 2 26 0  0 29 0 
Inconclusive 1 3 1  1 1 0 
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Table E5 Characteristics of participants with and without an evaluable culture result  
Variable  Evaluable culture 
result 
(n = 953) 
No evaluable culture 
result 
(n = 282) 
Sex Female (n, %) 619 (65.0) 169 (59.9) 
Age (years) Median (IQR) 36 (29-44) 36 (30-44) 
Body mass index (kg/m2) Median (IQR) 22.7 (20.2-26.8) 22.9 (20.1-26.5) 
Current symptoms Cough only (n, %) 218 (22.9) 67 (23.8) 
 Weight loss (n, %) 493 (51.7) 153 (54.3) 
 Fever (n, %) 395 (41.5) 116 (41.1) 
 Night sweats (n, %) 442 (46.5) 137 (48.9) 
Current TB treatment Yes (n, %) 37 (3.9) 11 (3.9) 
Previous TB treatment Yes (n, %) 368 (38.6) 121 (42.9) 
Current IPT use Yes (n, %) 15 (1.6) 1 (0.4) 
Risk of drug resistance Yes (n, %) 426 (44.7) 139 (49.3) 
HIV infection  Yes (n, %) 891 (93.6) 251 (89.0) 
Antiretroviral therapy* Current (n, %) 363/891 (40.7) 85/251 (33.9) 
CD4+ T-cell count (cells/µl)* Median (IQR) 277 (140-449) 238 (114-396) 
IPT, isoniazid preventive therapy; IQR, interquartile range 
* For HIV-infected participants only 
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Table E6 Comparison of baseline characteristics for participants with outcome evaluated vs. those lost to 
follow-up 
Variable  Outcome evaluated 
(n = 919) 
Lost to follow-up 
(n = 362) 
Sex Female (n, %) 593 (64.5) 222 (61.3) 
Age (years) Median (IQR) 36 (29-44) 36 (28-45) 
Body mass index (kg/m2) Median (IQR) 22.7 (20.1-26.7) 22.7 (20.3-26.9) 
Current symptoms Cough only (n, %) 218 (23.7) 86 (23.8) 
 Weight loss (n, %) 475 (51.7) 192 (53.0) 
 Fever (n, %) 357 (38.9) 168 (46.4) 
 Night sweats (n, %) 430 (46.9) 163 (45.2) 
Current IPT use Yes (n, %) 15 (1.6) 4 (1.1) 
Risk of drug resistance None (n, %) 494 (53.8) 210 (58.0) 
 Treatment failure (n, %) 10 (1.1) 1 (0.3) 
 Smear non-conversion (n, %) 25 (2.7)  12 (3.3) 
 Previous TB treatment (n, %) 373 (40.6) 127 (35.1) 
 Household contact (n, %) 28 (3.1) 9 (2.5) 
 Health care worker (n, %) 17 (1.9) 4 (1.1) 
 Prison last 12 months (n, %) 9 (1.0) 8 (2.2) 
HIV infection  Positive (n, %) 856 (93.1) 329 (90.9) 
 Negative (n, %) 52 (5.7) 26 (7.2) 
 Never tested (n, %) 5 (0.5) 4 (1.1) 
 Not disclosed (n, %) 6 (0.7) 2 (0.6) 
 Missing (n, %) 0 1 (0.3) 
Antiretroviral therapy* Current (n, %) 364 (42.5) 96 (29.2) 
CD4+ T-cell count (cells/µL)* Median (IQR) 256 (134-428) 286 (141-446) 
 ≤50 (n, %) 80 (9.4) 27 (8.2) 
 51-200 (n, %) 225 (26.3) 77 (23.4) 
 201-350 (n, %) 223 (26.1) 84 (25.5) 
 351-500 (n, %) 117 (13.7) 49 (14.9) 
 >500 (n, %) 144 (16.8) 56 (17.0) 
 Missing 67 (7.8) 26 (10.9) 
HIV RNA (copies/ml)† <400 (n, %) 206 (81.8) 60 (82.2) 
 <40 (n, %)  190 (75.4) 54 (74.0) 
* Proportions are of HIV-infected participants 
† Proportions are of HIV-infected participants on ART for more than three months
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Figure E1 Clinical management algorithm according to Xpert MTB/RIF results for participants not currently on TB treatment  
* Repeat test allowed on same specimen or additional specimen  
Xpert MTB/RIF
MTB detected
RIF resistance not detected
Commence standard TB treatment 
(2HRZE/4HR)
MTB detected
RIF resistance detected
Repeat Xpert MTB/RIF on same 
specimen and/or additional 
specimen
MTB detected
RIF resistance detected
Refer for DR-TB treatment
MTB detected
RIF resistance not detected
Commence standard TB treatment 
(2HRZE/4HR) & refer to medical 
officer
MTB not detected or 
error/invalid/no result
No TB treatment
Refer to medical officer
MTB not detected
Antibiotic therapy
Instruct participant to return after 
14 days if remains symptomatic
If remains symptomatic, refer for 
chest X-ray and medical officer 
review
Error/invalid/no result
Repeat Xpert MTB/RIF*
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Figure E2 Clinical management algorithm according to Xpert MTB/RIF results for participants currently on TB treatment 
 
* Repeat test allowed on same specimen or additional specimen 
  
Xpert MTB/RIF
MTB detected
RIF resistance not 
detected
Smear non-conversion at 
month 2 (standard regimen) 
or month 3 (retreatment 
regimen)
Continue HRZE for extra 
month
Repeat AFB smear at end of 
month
Check for culture/DST results
Treatment failure after month 
5 (standard regimen) or 
month 7 (retreatment 
regimen)
Register as treatment failure
Refer to medical officer
MTB detected
RIF resistance detected
Repeat Xpert MTB/RIF 
on same specimen and/or 
extra specimen
MTB detected
RIF resistance detected
Refer for DR-TB 
treatment
MTB detected
RIF resistance not 
detected
Continue current 
treatment
Refer to medical officer
MTB not detected or 
error/invalid/no result
Continue current 
treatment
Refer to medical officer
MTB not detected
Ensure that culture/DST 
specimen sent
Continue current treatment
Refer to medical officer
Error/invalid/no result
Repeat Xpert MTB/RIF*
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Figure E3 Final outcomes at day 60 for all participants, according to study arm and evidence of TB  
 
* Microbiological evidence of TB included positive M. tuberculosis culture and/or positive Xpert MTB/RIF  
1281 participants
Laboratory
640
Microbiological 
evidence of TB*
116
Alive, on TB 
treatment
88 (75.9%)
Alive, not on TB 
treatment
13 (11.2%)
Dead
2 (1.7%)
Outcome unknown
13 (11.2%)
No microbiological 
evidence of TB
524
Alive, on TB 
treatment
19 (3.6%)
Alive, not on TB 
treatment
333 (63.5%)
Dead
6 (1.1%)
Outcome unknown
166 (31.7%)
Point-of-care
641
Microbiological 
evidence of TB*
128
Alive, on TB 
treatment
96 (75.0%)
Alive, not on TB 
treatment
12 (9.4%)
Dead
12 (9.4%)
Outcome unknown
8 (6.3%)
No microbiological 
evidence of TB
513
Alive, on TB 
treatment
28 (5.5%)
Alive, not on TB 
treatment
306 (59.7%)
Dead
4 (0.8%)
Outcome unknown
175 (34.1%)
52 
 
References 
 
E1. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and 
operational 'How-to'; practical considerations. Geneva; 2011. 
E2. Department of Health RoSA. Multi-drug resistant tuberculosis. A policy framework on decentralised and 
deinstitutionalised management for South Africa. Pretoria, South Africa: Department of Health; 2011. 
E3. Department of Health RoSA. Management of drug-resistant tuberculosis: Policy guidelines. Pretoria: 
Department of Health; 2011. 
 
 
 
 
